Effect of hypercholesterolemia on long-term prognosis in patients with acute myocardial infarction depending on the age of patients

April 27, 2020

The aim was to identify and evaluate the effect of lipid metabolism on long-term prognosis in young patients after acute myocardial infarction (MI). Object and research methods. 142 patients, predominantly male, hospitalized with acute coronary syndrome with ST segment elevation during the period 2000–2015, and who were discharged from the hospital, depending on their age, are retrospectively divided into groups: 1st (n=55) — <45 and 2nd (n=87) — ≥45 years. Subsequently, depending on the baseline low-density lipoprotein (LDL) higher or less than 4.0 mmol/l, 4 subgroups were isolated: 1A (n=21) with LDL level ≥4.0, 1B (n=34) — <4.0, 2A (n=42) — ≥4.0 and 2B (n=45) — <4.0 mmol/L. All patients were examined during hospital stay (electrocardiography, echocardiography, coronary angiography, lipidogram), and the development of endpoints (death from any cause, combined and extended combined point) during 3 and 5 years of observation was performed, ROC-analysis was performed with determination of specificity and sensitivity of predictor of development of complications. Results.In young patients of the 1A subgroup, according to the results of the coronary angiography, three-vascular lesions (14.3 and 0%, respectively) were more often noted in comparison with the older age 2A subgroup and less frequently the absence of atherosclerotic lesions of the coronary vessels. Young patients with significant hyperlipidemia (1A subgroup) had a worse prognosis (death from any cause) within 3 years (Log-rank test; p=0.017), which had a trend tendency at 5 years (Log-rank test; p=0.085), compared with subgroup 1B. Patients in the 1A subgroup also more frequently reached the combined endpoint (cardiovascular death/recurrent MI/stroke) compared with subgroup 1B within 3 years (Log-rank test; p=0.021), but after 5 years the difference was absent (p=0.194). The greatest divergence of curves was noted at achievement of the extended combined point (cardiovascular death/recurrent MI/stroke/revascularization): in patients aged <45 years with LDL level ≥4.0 mmol/L for 3 and 5 years more often the development of complications was observed (Log-rank test; p=0.002 and p=0.021, respectively) compared with patients of the same age group with a LDL level <4.0 mmol/L. Patients of the older age group (≥45 years) had no dependence of development of complications on the baseline LDL level higher or less than 4.0 mmol/L. The LDL level 4.125 mmol/L proved to be prognostically significant for the development of cardiovascular complications in the outpatient period of MI only in young patients (area under the ROC-curve 0.746 (95% confidence interval 0.59–0.90). Conclusions. In patients with acute coronary syndrome with ST segment elevation <45years in the presence of ascending hyperlipidemia (LDL level >4.0 mmol/L), widespread coronary atherosclerosis, manifested in multi-vascular lesions, unlike the older age group. Baseline LDL level ≥4.0 mmol/L has a negative effect on the course of the postinfarction period in young patients, increasing the number of complications during the 5 years of follow-up. Patients with premature development of acute MI and high LDL level, as high-risk patients, should be subjected to an individualized approach to treatment and secondary prevention with maximum active hypolipidemic therapy.

Published: 27.04.2020


  • Parkhomenko O.M., Amosova K.M., Dziak H.V. ta in. (2013) Rekomendatsii Asotsiatsii kardiolohiv Ukrainy shchodo vedennia patsiientiv z hostrym koronarnym syndromom z elevatsiieiu sehmenta ST. UKZh, dodatok 3.
  • Parkhomenko O.M., Lutai Ya.M., Irkin O.I. ta in. (2018) Kliniko-anamnestychna kharakterystyka ta perebih hospitalnoho periodu zakhvoriuvannia u khvorykh molodoho viku z hostrym koronarnym syndromom z elevatsiieiu sehmenta ST. UKZh, 25(4): 31–39. DOI: https://doi.org/10.31928/1608-635X-2018.4.3139.
  • Abdullah Sh.M., Defina L.F., Leonard D. et al. (2018) Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Dise ase Circulation, 138: 2315–2325. https://doi.org/10.1161/CIRCULATIONAHA.118.034273.
  • Aggarwal A., Aggarwal S., Goel A. et al. (2012) A retrospective case-control study of modifiable risk factors and cutaneous markers in Indian patients with young coronary artery disease. JRSM Cardiovasc. Dis., 1(3): cvd.2012.012010. doi: 10.1258/cvd.2012.012010. eCollection 2012.
  • Arnett D.K., Blumenthal R.S., Albert M.A. et al. (2019) 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 74: 1376–1414.
  • Cannon C.P., Blazing M.A., Giugliano R.P. et al.; IMPROVE-IT Investigators (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N. Engl. J. Med., 372(25): 2387–2397.
  • Castellano J.M., Sanz G., Peñalvo J.L. et al. (2014) A polypill strategy to improve adherence: results from the FOCUS project. J. Am. Coll. Cardiol., 64: 2071–2082. doi: 10.1016/j.jacc.2014.08.021.
  • Chan C.M., Chen W.L., Kuo H.Y. et al. (2012) Circadian variation of acute myocardial infarction in young people. Am. J. Emerg. Med., 30: 1461–1465.
  • Chan M.Y., Woo K.S., Wong H.B. et al. (2006) Antecedent risk factors and their control in young patients with a first myocardial infarction. Singapore Med. J., 47: 27–30.
  • Cholesterol Treatment Trialists Collaboration, Baigent C., Blackwell L., Emberson J. et al. (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomised trials. Lancet. 376: 16701681. https://doi.org/10.1016/S0140-6736(10)61350-5.
  • Collet J.-Ph., Zeitouni M., Procopi N. et al. (2019) Long-Term Evolution of Premature Coronary Artery Disease. J. Am. Coll. Cardiol., 74(15): 1868–1878.
  • Conroy R.M., Pyörälä K., Fitzgerald A.P. et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J., 24(11): 987–1003. https://doi.org/10.1016/S0195-668X(03)00114-3).
  • Degli Esposti L., Saragoni S., Batacchi P. et al. (2012) Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin. Ther., 34: 190–199. doi: 10.1016/j.clinthera.2011.12.011.
  • Duzen I.V., Cekici Y. (2019) Predictors of multivessel involvement in patients under 40 years of age receiving primary PTCA for STEMI. Ann. Med. Res., 26(9): 1825–1831. DOI: 10.5455/annalsmedres.2019.07.396.
  • Emerging Risk Factors Collaboration, Di Angelantonio E., Gao P., Pennells L. et al. (2012) Lipid-related markers and cardiovascular disease prediction. JAMA, 307: 24992506.
  • Ference B.A., Yoo W., Alesh I. et al. (2012) Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J. Am. Coll. Cardiol., 60: 26312639.
  • Force USPST, Bibbins-Domingo K., Grossman D.C. et al. (2016) Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. JAMA, 316: 1997–2007.
  • Fournier J.A., Sanchez A., Quero J. et al. (1996) Myocardial infarction in men aged 40 years or less: a prospective clinical-angiographic study. Clin. Cardiol., 19: 631–636.
  • Grundy S.M., Stone N.J., Bailey A.L. et al. (2018) 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol., Nov. 8 [Epub ahead of print].
  • Hosseini S.K., Soleimani A., Karimi A.A. et al. (2009) Clinical features, management and in-hospital outcome of ST elevation myocardial infarction (STEMI) in young adults under 40 years of age. Monaldi Arch. Chest Dis., 72(2): 71–76. DOI: 10.4081/monaldi.2009.331.
  • Kannel W.B., Abbott R.D. (1984) Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study. N. Engl. J. Med., 311: 1144–1147.
  • Klag M.J., Ford D.E., Mead L.A. et al. (1993) Serum cholesterol in young men and subsequent cardiovascular disease. N. Engl. J. Med., 328: 313–318. doi: 10.1056/NEJM19930204328050.
  • Mach F., Baigent C., Catapano A.L. et al.; ESC Scientific Document Group (2019) 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur. Heart J., 41(1): 111–188. https://doi.org/10.1093/eurheartj/ehz455.
  • McManus D.D., Piacentine S.M., Lessard D. et al. (2011) Thirty-year (1975 to 2005) trends in the incidence rates, clinical features, treatment practices, and short-term outcomes of patients <55 years of age hospitalized with an initial acute myocardial infarction. Am. J. Cardiol., 108: 477–482.
  • Michos E.D., Choi A.D. (2019) Coronary Artery Disease in Young Adults. J. Am. Coll. Cardiol., 74(15): 1879–1882. doi:10.1016/j.jacc.2019.08.1023.
  • Navarese E.P., Kowalewski M., Andreotti F. et al. (2014) Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am. J. Cardiol., 113: 1753–1764.
  • Nordestgaard B.G., Chapman M.J., Humphries S.E. et al. (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J., 34: 3478—3490.
  • Piepoli M.F., Hoes A.W., Agewall S. et al. (2016) 2016 European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J., 37: 2315–2381.
  • Ray K.K., Cannon C.P., McCabe C.H. et al.; ROVE IT-TIMI 22 Investigators (2005) Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J. Am. Coll. Cardiol., 46(8): 1405–1410.
  • Schwartz G.G., Olsson A.G., Ezekowitz M.D. et al.; Myocardial Ischemia Reductionwith Aggressive Cholesterol Lowering (MIRACL) Study Investigators (2001) Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 285: 1711–1718.
  • Shah N., Kelly A.M., Cox N. et al. (2016) Myocardial Infarction in the «Young»: Risk Factors, Presentation, Management and Prognosis. Heart Lung Circ., 25(10): 955–960. doi: 10.1016/j.hlc.2016.04.015.
  • Silverman M.G., Ference B.A., Im K. et al. (2016) Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 316: 1289–1297.
  • Steg P.G., James S.K., Atar D. et al. (2012) Task Force on the management of ST-segment Elevation Acute Myocardial Infarction of the European Society of Cardiolo­gy. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J., 33: 2569–2619.
  • Stone N.J., Robinson J.G., Lichtenstein A.H. et al. (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol., 63: 2889–934.
  • Whelton P.K., Carey R.M., Aronow W.S. et al. (2018) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol., 71: e127–e248.
  • Wolfe M.W., Vacek J.L. (1988) Myocardial infarction in the young. Angiographic features and risk factor analysis of patients with myocardial infarction at or before the age of 35 years. Chest, 94: 926–930.
  • Zimmerman F.H., Cameron A., Fisher L.D., Ng G. (1995) Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). J. Am. Coll. Cardiol., 26: 654–661.